Bliss GVS Pharma Ltd

NSE
BLISSGVS •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Bliss GVS Pharma Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
84.90% Gain from 52W Low
-7.7
TTM PE Ratio
Below industry Median
15.2
Price to Book Ratio
Low in industry
1.5
Dividend yield 1yr %
Below industry Median
0.4
TTM PEG Ratio
PEG TTM is much higher than 1
16.6
RSI
RSI is mid-range
57.2
MFI
MFI Overbought
77.5

Bliss GVS Pharma Ltd Key Financials

*All values are in ₹ Cr.

Bliss GVS Pharma Ltd shareholding Pattern

Promoter
35%
Foreign Institutions
15.4%
Domestic Institutions
6.6%
Public
43.1%

Bliss GVS Pharma Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
126.60
10Day EMA
123.80
12Day EMA
123.10
20Day EMA
122.20
26Day EMA
122.20
50Day EMA
121.80
100Day EMA
116.60
200Day EMA
106.50
Delivery & Volume
Resistance & Support
128.02
Pivot
Resistance
First Resistance
132.23
Second Resistance
136.52
Third Resistance
140.73
Support
First Support
123.73
Second support
119.52
Third Support
115.23
Relative Strength Index
57.22
Money Flow Index
77.47
MACD
0.96
MACD Signal
-0.82
Average True Range
7.19
Average Directional Index
15.81
Rate of Change (21)
1.39
Rate of Change (125)
39

Bliss GVS Pharma Ltd Company background

Founded in: 1984
Managing director: Gagan Harsh Sharmma
Bliss GVS Pharma Ltd is an exportoriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial, antifungal, antibacterial, antiinflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EUGMP certified suppositories manufacturer in India.The company has a dedicated the RD Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific Industrial Research (DSIR), Government of India.Incorporated in 1984 as a private limited company under the name Bliss Chemicals Pharmaceuticals India Ltd, the company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID.During the financial year ended 31 March 2014, Bliss GVS Pharmas RD center, received approval from Government of Indias Department for Scientific Industrial Research (DSIR).During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd. During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. The business is now backing on track in Ghana.During the year ended 31 March 2015, Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent.During the financial year ended 31 March 2016, Bliss GVS Pharma continued to grow in various geographies in Kenya, Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria. Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017,The companys investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon. This presents a great platform for the unit to build on its recent success to successfully bid for other such contracts. During the year ended 31 March 2018, Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited, Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited, Nairobi to focus on its core pharmaceutical operations, which have been a steady source of growth.As on 31 March 2019,the company has one domestic and 3 overseas subsidiaries.During the FY2020,the Company has completed the commissioning qualification of PhaseI for its new state of the art multiproduct facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with stateoftheart process equipment utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the Company. The Company has 4 wholly owned subsidiaries and 3 stepdown subsidiaries as on 31 March 2020. During the year, ECO Rich Cosmetics India Private Limited discontinued or ceased to be a stepdown subsidiary of the Company consequent to loss of control. The Companys wholly owned subsidiary Bliss GVS Clinic HealthCare Pte. Ltd. situated at Singapore became a material subsidiary for the Company during the financial year 20192020.
Read More

Bliss GVS Pharma Ltd FAQs

Bliss GVS Pharma Ltd shares are currently priced at 127.95 on NSE and 127.85 on BSE as of 2/20/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Bliss GVS Pharma Ltd [BLISSGVS] share was 63.51. The Bliss GVS Pharma Ltd [BLISSGVS] share hit a 1-year low of Rs. 69.2 and a 1-year high of Rs. 149.6.

The market cap of Bliss GVS Pharma Ltd is Rs. 1339.52 Cr. as of 2/20/2024 12:00:00 AM.

The PE ratios of Bliss GVS Pharma Ltd is 19.61 as of 2/20/2024 12:00:00 AM.

The PB ratios of Bliss GVS Pharma Ltd is 1.36 as of 2/20/2024 12:00:00 AM

You can easily buy Bliss GVS Pharma Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage